2 news items
Lineage Cell Therapeutics Announces OpRegen Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit
LCTX
6 May 24
approved recently for the treatment of GA secondary to AMD have not demonstrated a compelling functional benefit, so there remains
OpRegenĀ® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
LCTX
6 May 24
benefit, so there remains a need for treatments that can positively affect patient vision," stated Brian M. Culley, Lineage CEO. "We are encouraged
- Prev
- 1
- Next